- Home
- UPXI vs IMAB Comparison
UPXI vs IMAB Comparison
Compare UPXI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- IMAB
- Stock Information
- Founded
- UPXI 2018
- IMAB 2014
- Country
- UPXI United States
- IMAB United States
- Employees
- UPXI N/A
- IMAB N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- IMAB Health Care
- Exchange
- UPXI Nasdaq
- IMAB Nasdaq
- Market Cap
- UPXI 481.8M
- IMAB 394.2M
- IPO Year
- UPXI 2021
- IMAB 2020
- Fundamental
- Price
- UPXI $7.14
- IMAB $4.39
- Analyst Decision
- UPXI
- IMAB Strong Buy
- Analyst Count
- UPXI 0
- IMAB 6
- Target Price
- UPXI N/A
- IMAB $7.17
- AVG Volume (30 Days)
- UPXI 6.2M
- IMAB 1.7M
- Earning Date
- UPXI 09-24-2025
- IMAB 11-02-2025
- Dividend Yield
- UPXI N/A
- IMAB N/A
- EPS Growth
- UPXI N/A
- IMAB N/A
- EPS
- UPXI N/A
- IMAB N/A
- Revenue
- UPXI $15,811,345.00
- IMAB N/A
- Revenue This Year
- UPXI $145.75
- IMAB N/A
- Revenue Next Year
- UPXI N/A
- IMAB N/A
- P/E Ratio
- UPXI N/A
- IMAB N/A
- Revenue Growth
- UPXI N/A
- IMAB N/A
- 52 Week Low
- UPXI $1.90
- IMAB $0.60
- 52 Week High
- UPXI $22.57
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- UPXI 54.39
- IMAB 59.97
- Support Level
- UPXI $5.01
- IMAB $3.98
- Resistance Level
- UPXI $7.75
- IMAB $4.51
- Average True Range (ATR)
- UPXI 0.48
- IMAB 0.30
- MACD
- UPXI 0.18
- IMAB 0.07
- Stochastic Oscillator
- UPXI 77.19
- IMAB 89.30
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).